Medivir Logo

Medivir

ISIN: SE0000273294 | Ticker: MVIR | LEI: 549300VWDGUX0WMJ1T79
Sector: Health Care – Sub-Industry: Pharmaceuticals
Country: Sweden

About Medivir

Company Description

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors.

Year founded

1988

Headquarters

Lunastigen 5, 2nd floor, 14122 Huddinge – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 191,462,000.00 335,825,000.00 234,197,000.00
Noncurrent Assets N/A 112,531,000.00 109,909,000.00 111,153,000.00
Property Plant And Equipment N/A 16,211,000.00 13,597,000.00 14,841,000.00
Other Property Plant And Equipment N/A 92,000.00 0.00 340,000.00
Intangible Assets Other Than Goodwill N/A 96,320,000.00 96,312,000.00 96,312,000.00
Intangible Assets Under Development N/A 96,312,000.00 96,312,000.00 96,312,000.00
Other Intangible Assets N/A 8,000.00 0.00 0.00
Other Noncurrent Financial Assets N/A 0.00 0.00 0.00
Current Assets N/A 78,931,000.00 225,917,000.00 123,044,000.00
Current Trade Receivables N/A 15,000.00 N/A N/A
Other Current Receivables N/A 3,199,000.00 1,294,000.00 1,379,000.00
Current Tax Assets Current N/A 778,000.00 1,446,000.00 1,446,000.00
Cash and cash equivalents 134,509,000.00 70,007,000.00 221,167,000.00 117,434,000.00
Cash N/A 14,038,000.00 14,690,000.00 6,448,000.00
Cash Equivalents N/A 55,969,000.00 206,477,000.00 110,986,000.00
Equity And Liabilities N/A 191,462,000.00 335,825,000.00 234,197,000.00
Equity 184,456,000.00 141,905,000.00 281,146,000.00 192,789,000.00
Issued Capital N/A 188,494,000.00 27,868,000.00 27,868,000.00
Retained Earnings N/A -463,655,000.00 -548,419,000.00 -637,184,000.00
Additional Paidin Capital N/A 420,804,000.00 804,944,000.00 805,349,000.00
Noncurrent Liabilities N/A 14,888,000.00 12,964,000.00 13,399,000.00
Current Liabilities N/A 34,670,000.00 41,716,000.00 28,009,000.00
Trade And Other Current Payables To Trade Suppliers N/A 6,808,000.00 10,338,000.00 3,763,000.00
Accruals Classified As Current N/A 25,414,000.00 29,171,000.00 20,673,000.00
Other Current Payables N/A 848,000.00 1,153,000.00 1,460,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Royalties 13,948,000.00 25,538,000.00 4,408,000.00
Employee Benefits Expense 24,931,000.00 21,415,000.00 20,735,000.00
Depreciation And Amortisation Expense 4,430,000.00 2,595,000.00 2,571,000.00
Other Expense By Nature 52,932,000.00 73,277,000.00 69,078,000.00
Profit Loss From Operating Activities -42,900,000.00 -62,118,000.00 -87,354,000.00
Finance Income 827,000.00 490,000.00 8,000.00
Finance Costs 547,000.00 950,000.00 1,419,000.00
Profit Loss Before Tax -42,620,000.00 -62,579,000.00 -88,765,000.00
Income Tax Expense Continuing Operations N/A 546,000.00 N/A
Profit (loss) -42,620,000.00 -63,125,000.00 -88,765,000.00
Profit Loss Attributable To Owners Of Parent -42,620,000.00 -63,125,000.00 -88,765,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -42,620,000.00 -63,125,000.00 -88,765,000.00
Other Adjustments For Noncash Items N/A -13,937,000.00 2,622,000.00 2,571,000.00
Cash Flows From Used In Operations N/A -56,557,000.00 -59,957,000.00 -86,194,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A -799,000.00 1,214,000.00 N/A
Other Inflows Outflows Of Cash Classified As Operating Activities N/A 6,346,000.00 N/A N/A
Cash Flows From Used In Operating Activities N/A -58,053,000.00 -48,734,000.00 -101,820,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 1,706,000.00 N/A N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 2,684,000.00 0.00 382,000.00
Cash Flows From Used In Investing Activities N/A 5,368,000.00 0.00 -382,000.00
Proceeds From Issuing Shares N/A N/A 222,763,000.00 0.00
Proceeds From Issuing Other Equity Instruments N/A 595,000.00 752,000.00 404,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 12,713,000.00 2,475,000.00 1,940,000.00
Cash Flows From Used In Financing Activities N/A -12,118,000.00 199,400,000.00 -1,535,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -64,803,000.00 150,666,000.00 -103,737,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 301,000.00 494,000.00 3,000.00
Cash and cash equivalents 134,509,000.00 70,007,000.00 221,167,000.00 117,434,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
15.11.22 Fredrik Öberg Other Buy SEK 77,000.00
14.11.22 Jens Anders Fredrik Lindberg Other Buy SEK 192,500.00
14.11.22 Magnus Christensen Other Buy SEK 115,500.00
28.03.22 Jens Anders Fredrik Lindberg Other Buy SEK 122,850.00
25.03.22 Jens Anders Fredrik Lindberg Other Buy SEK 80,000.00
03.03.22 Magnus Christensen Other Buy SEK 46,800.00
23.12.21 Malene Jensen Other Buy SEK 25,650.00
13.12.21 Malene Jensen Other Buy SEK 109,500.00
13.12.21 Malene Jensen Other Buy SEK 85,500.00
13.05.21 Fredrik Öberg Other Buy SEK 97,500.00

Capital markets information

ISIN

SE0000273294

LEI

549300VWDGUX0WMJ1T79

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.